These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36425583)

  • 1. The serum acylcarnitines profile in epileptic children treated with valproic acid and the protective roles of peroxisome proliferator-activated receptor
    Ma Y; Wang M; Guo S; Li T; Liu X; Zhao L
    Front Pharmacol; 2022; 13():1048728. PubMed ID: 36425583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPARα activation protects against cholestatic liver injury.
    Zhao Q; Yang R; Wang J; Hu DD; Li F
    Sci Rep; 2017 Aug; 7(1):9967. PubMed ID: 28855630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
    Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
    Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid induced liver injury: An insight into molecular toxicological mechanism.
    Ezhilarasan D; Mani U
    Environ Toxicol Pharmacol; 2022 Oct; 95():103967. PubMed ID: 36058508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Protective Roles of PPARα Activation in Triptolide-Induced Liver Injury.
    Hu DD; Zhao Q; Cheng Y; Xiao XR; Huang JF; Qu Y; Li X; Tang YM; Bao WM; Yang JH; Jiang T; Hu JP; Gonzalez FJ; Li F
    Toxicol Sci; 2019 Sep; 171(1):1-12. PubMed ID: 31241159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Butyrate prevents valproate-induced liver injury: In vitro and in vivo evidence.
    Pirozzi C; Lama A; Annunziata C; Cavaliere G; De Caro C; Citraro R; Russo E; Tallarico M; Iannone M; Ferrante MC; Mollica MP; Mattace Raso G; De Sarro G; Calignano A; Meli R
    FASEB J; 2020 Jan; 34(1):676-690. PubMed ID: 31914696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum metabolomics reveals irreversible inhibition of fatty acid beta-oxidation through the suppression of PPARalpha activation as a contributing mechanism of acetaminophen-induced hepatotoxicity.
    Chen C; Krausz KW; Shah YM; Idle JR; Gonzalez FJ
    Chem Res Toxicol; 2009 Apr; 22(4):699-707. PubMed ID: 19256530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis.
    Aires CC; Ijlst L; Stet F; Prip-Buus C; de Almeida IT; Duran M; Wanders RJ; Silva MF
    Biochem Pharmacol; 2010 Mar; 79(5):792-9. PubMed ID: 19854160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update.
    Guo HL; Jing X; Sun JY; Hu YH; Xu ZJ; Ni MM; Chen F; Lu XP; Qiu JC; Wang T
    Curr Pharm Des; 2019; 25(3):343-351. PubMed ID: 30931853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential induction of genes in liver and brown adipose tissue regulated by peroxisome proliferator-activated receptor-alpha during fasting and cold exposure in acyl-CoA dehydrogenase-deficient mice.
    Goetzman ES; Tian L; Wood PA
    Mol Genet Metab; 2005 Jan; 84(1):39-47. PubMed ID: 15639194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of valproic acid on the expression of various acyl-CoA dehydrogenases in rats.
    Kibayashi M; Nagao M; Chiba S
    Pediatr Int; 1999 Feb; 41(1):52-60. PubMed ID: 10200137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TXNIP/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation.
    Park HS; Song JW; Park JH; Lim BK; Moon OS; Son HY; Lee JH; Gao B; Won YS; Kwon HJ
    Autophagy; 2021 Sep; 17(9):2549-2564. PubMed ID: 33190588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of a high-fat diet and chronic valproic acid treatment on hepatic steatosis and hepatotoxicity in rats.
    Zhang LF; Liu LS; Chu XM; Xie H; Cao LJ; Guo C; A JY; Cao B; Li MJ; Wang GJ; Hao HP
    Acta Pharmacol Sin; 2014 Mar; 35(3):363-72. PubMed ID: 24442146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores.
    Knapp AC; Todesco L; Beier K; Terracciano L; Sägesser H; Reichen J; Krähenbühl S
    J Pharmacol Exp Ther; 2008 Feb; 324(2):568-75. PubMed ID: 17986647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.
    Silva MF; Aires CC; Luis PB; Ruiter JP; IJlst L; Duran M; Wanders RJ; Tavares de Almeida I
    J Inherit Metab Dis; 2008 Apr; 31(2):205-16. PubMed ID: 18392741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysregulations of UDP-glucuronosyltransferases in rats with valproic acid and high fat diet induced fatty liver.
    Zhang L; Chu X; Wang H; Xie H; Guo C; Cao L; Zhou X; Wang G; Hao H
    Eur J Pharmacol; 2013 Dec; 721(1-3):277-85. PubMed ID: 24056123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.
    Takei K; Han SI; Murayama Y; Satoh A; Oikawa F; Ohno H; Osaki Y; Matsuzaka T; Sekiya M; Iwasaki H; Yatoh S; Yahagi N; Suzuki H; Yamada N; Nakagawa Y; Shimano H
    J Diabetes Investig; 2017 Jul; 8(4):446-452. PubMed ID: 28084058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.
    Lakhia R; Yheskel M; Flaten A; Quittner-Strom EB; Holland WL; Patel V
    Am J Physiol Renal Physiol; 2018 Jan; 314(1):F122-F131. PubMed ID: 28903946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.